Post-Operative Pain
Conditions
Brief summary
The purpose of this Phase 2 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections. The study is designed as randomized, double-blind, parallel, placebo-controlled study.
Detailed description
VVZ-149 is a dual antagonist of GlyT2 and 5HT2A. GlyT2 blockage increases inhibitory synaptic transmission by glycine in the spinal cord, resulting in a reduction of pain transmissions to the brain. 5HT2A blockage decreases descending serotonergic facilitatory modulation on pain transmission by the brain and reduces nociceptor activation in peripheral nerves, which are primary sources of pain in post-surgical pain. VVZ-149 has been shown to have comparable efficacy to morphine in well controlled (blind, complete randomization with a positive control) animal studies using rat models of post-operative pain and formalin-induced pain. The PK/PD study in animals indicates that therapeutic plasma concentration in human subjects will be 600-1,900 ng/ml. A clinical Phase 1 study performed in healthy subjects has shown no clinically significant adverse events up to a plasma concentration level of 3,261 ng/ml other than brief symptoms of mild nausea or dizziness, and mild somnolence when the plasma exposure level is more than 2,000 ng/ml.
Interventions
Experimental group will receive a loading dose of 1.8 mg/kg VVZ-149 intravenous infusion for 0.5 hour followed by a maintenance dose of 1.3 mg/kg/h VVZ-149 intravenous infusion for 7.5 hours.
DRUGPlacebo
Placebo group will receive the corresponding amount of placebo.
Sponsors
Vivozon, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Men and women age between 18-70, inclusive. 2. Pain intensity (NRS) ≥4 at initial post-operative measurement in PACU. 3. Subjects undergoing planned laparoscopic colorectal surgery. 4. Ability to provide written informed consent. 5. Ability to understand study procedures and communicate clearly with the investigator and staff. 6. American Society of Anesthesiologists (ASA) risk class of I to III.
Exclusion criteria
\< Surgical Factors \> 1. Emergency or unplanned surgery. 2. Repeat operation (e.g., previous surgery within 30 days for same condition). 3. Cancer-related condition causing preoperative pain in site of surgery. \< Subject Characteristics \> 4. Women with childbearing potential (Women age 18-55 must undergo pregnancy test). 5. Women who are pregnant or breastfeeding. 6. Chronic pain diagnosis (e.g., ongoing pain at baseline with NRS ≥ 4/10). 7. Unstable or poorly controlled psychiatric condition (e.g., untreated PTSD, anxiety, or depression) Subjects who take stable doses (same dose \>30 days) of antidepressants and anti-anxiety drugs may be included. 8. Unstable or acute medical condition (e.g., unstable angina, congestive heart failure, renal failure, hepatic failure, AIDS). \< Drug, Alcohol, and Pharmacological Considerations \> 9. Renal or hepatic impairment. 10. History of alcohol, opiate or other drug abuse or dependence within 12 months prior to Screening (TICS alcohol/drug screen will be performed at Screening). 11. Ongoing or recent (within 30 days prior to surgery) use of steroids, opioids, or antipsychotics. 12. Alcohol consumption within 24 hours of surgery. 13. Use of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen within 24 hours of surgery. 14. Use of herbal agents or nutraceuticals (i.e., chaparral, comfrey, germander, jin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian) within 7 days prior to surgery. \< Anesthetic and Other Exclusion Considerations \> 15. Use of neuraxial or regional anesthesia related to the surgery. 16. Use of local anesthetic wound infiltration \> 20 ml of 1% lidocaine 17. Use of ketamine, gabapentin, pregabalin, or lidocaine (\>1 mg/kg) intra or peri-operatively, or within 24 hours of surgery. 18. Subjects with known allergies to hydromorphone. 19. Subjects who received another investigational drug within 30 days of scheduled surgery. 20. Subjects who have long PR (\>200 msec) or prolonged QTc (\> 450 msec) at Screening or on an EKG done immediately prior to dosing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sum of Pain Intensity Difference over 8-hours post-dose (SPID8) | 8 hours post-dose | SPID8 using Numerical Pain Rating Scale (NRS, 0-10) measured up to 8 hours post-dose |
Secondary
| Measure | Time frame |
|---|---|
| Change of Pain Intensity (NRS) | 9 and 24 hours post-dose |
| Change of Pain Relief (PR) assessed using a 6-point categorical scale | 9 and 24 hours post-dose |
| Difference of Opioid Consumption between Study Groups | 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, and 16-24 hours post-dose |
| Change of Richmond Agitation-Sedation Scale | 9 and 24 hours post-dose |
| Change of Incidence of Postoperative Nausea and Vomiting | 8 and 24 hours post-dose |
| Comparison of Global Measurement of Subject Satisfaction between Study Groups | 8 and 24 hours post-dose |
Countries
United States
Outcome results
None listed